Total assets rose from $50.0B to $57.3B while equity moved only from $17.6B to $18.8B, with a debt-to-equity ratio of 0.73, suggesting moderate leverage but a balance sheet growing faster through liabilities than retained capital.
Humana Inc. (HUM) balance sheet — 30-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Assets | 57.28B | 48.75B | 46.31B | 46.89B | 43.73B | 44.75B | 35.08B | 29.04B | 25.34B | 26.68B | 25.81B | 25.12B | 23.45B | 20.77B | 19.52B | 17.86B | 16.07B | 14.15B | 13.04B | 12.88B | 10.13B | 6.87B | 5.66B | 5.29B | 4.6B | 4.4B | 4.17B | 4.9B | 5.5B | 5.42B | 3.15B |
| Asset Growth % | 42.6% | 5.26% | -1.24% | 7.24% | -2.29% | 27.57% | 20.78% | 14.6% | -5.02% | 3.38% | 2.74% | 7.13% | 12.9% | 6.42% | 9.29% | 11.12% | 13.55% | 8.52% | 1.26% | 27.17% | 47.42% | 21.42% | 6.88% | 15.07% | 4.46% | 5.68% | -14.96% | -10.84% | 1.44% | 71.84% | 9.56% |
| Total Investment Assets | 4M | 16.83B | 19.33B | 17.75B | 15.01B | 14.11B | 14.94B | 12.44B | 11.48B | 12.3B | 9.8B | 9.11B | 9.55B | 9.8B | 9.85B | 9.45B | 8.37B | 7.62B | 5.62B | 5.99B | 4.24B | 0 | 2.15B | 2B | 1.69B | 1.67B | 1.65B | 1.76B | 1.9B | 2.02B | 1.41B |
| Long-Term Investments | 19.97B | 16.83B | 19.33B | 17.75B | 15.01B | 14.11B | 14.94B | 12.44B | 11.48B | 12.3B | 9.8B | 9.11B | 9.55B | 9.8B | 9.85B | 9.45B | 8.37B | 7.62B | 5.62B | 5.99B | 4.24B | 0 | 0 | 319.17M | 288.72M | 280.32M | 240M | 1.51B | 1.59B | 1.51B | 1.26B |
| Short-Term Investments | 18.17B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.15B | 1.68B | 1.41B | 1.39B | 1.41B | 1.51B | 1.59B | 1.51B | 1.26B |
| Total Current Assets | 39.61B | 7.47B | 4.92B | 6.73B | 6.74B | 5.21B | 5.81B | 5.11B | 3.36B | 4.9B | 4.7B | 3.41B | 2.71B | 1.8B | 1.79B | 2.18B | 2.32B | 2.8B | 3.11B | 2.97B | 2.65B | 4.08B | 3.52B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 6.93B | 4.2B | 2.22B | 4.69B | 5.06B | 3.39B | 4.67B | 4.05B | 2.34B | 4.04B | 3.88B | 2.57B | 1.94B | 1.14B | 1.31B | 1.38B | 1.67B | 1.61B | 1.97B | 2.04B | 1.74B | 732.02M | 580.08M | 931.4M | 721.36M | 651.42M | 658M | 978M | 913M | 627M | 322M |
| Receivables | 17.05B | 3.27B | 2.7B | 2.04B | 1.67B | 1.81B | 1.14B | 1.06B | 1.01B | 854M | 1.28B | 1.16B | 1.05B | 950M | 733M | 1.03B | 959M | 823.62M | 789.68M | 605.54M | 680.94M | 738.65M | 579.62M | 465.99M | 321.13M | 322.06M | 205.26M | 225M | 276M | 351M | 211M |
| Other Current Assets | 11.63B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -461M | -319M | -283M | -287M | -252M | -230M | -316.08M | 366.48M | 353.79M | 328.82M | 229.42M | 380.61M | 212.96M | -3.07B | -2.45B | -2.36B | -2.27B | -2.71B | -2.78B | -2.48B | -1.79B |
| Goodwill & Intangibles | 42.34B | 10.81B | 11.07B | 11.24B | 10.91B | 13.73B | 4.78B | 4.11B | 4.14B | 3.51B | 3.55B | 3.62B | 3.67B | 4.43B | 4.37B | 3.17B | 2.97B | 2.24B | 2.26B | 1.9B | 1.41B | 1.37B | 915.89M | 776.87M | 776.87M | 776.87M | 790M | 806M | 1.19B | 1.22B | 488M |
| Goodwill | 10.55B | 9.69B | 9.63B | 9.55B | 9.14B | 11.09B | 4.45B | 3.93B | 3.9B | 3.28B | 3.27B | 3.27B | 3.23B | 3.73B | 3.64B | 2.74B | 2.57B | 1.99B | 1.96B | 1.66B | 1.31B | 1.26B | 885.57M | 776.87M | 776.87M | 776.87M | 790M | 806M | 1.19B | 1.22B | 488M |
| Intangible Assets | 0 | 1.13B | 1.44B | 1.69B | 1.76B | 2.64B | 329M | 177M | 245M | 226M | 280M | 357M | 440M | 693M | 731M | 435M | 399.47M | 243.47M | 301.29M | 236.77M | 95.66M | 104.02M | 30.32M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PP&E (Net) | 2.07B | 2.72B | 2.98B | 3.54B | 3.74B | 3.75B | 2.81B | 2.37B | 1.74B | 1.58B | 1.5B | 1.38B | 1.23B | 1.22B | 1.1B | 912M | 815.34M | 679.14M | 711.49M | 637.24M | 545M | 484.41M | 399.51M | 416.47M | 459.84M | 461.76M | 435M | 418M | 433M | 420M | 371M |
| Other Assets | 3.83B | 10.83B | 7.74B | 7.58B | 6.49B | 7.37B | 6.44B | 4.79B | 4.38B | 3.85B | 5.45B | 6.89B | 5.57B | 2.84B | 2.42B | 1.52B | 1.05B | 748.92M | 1.18B | 1.36B | 1.26B | -1.92B | 823.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 38.4B | 31.01B | 29.87B | 30.57B | 28.36B | 28.64B | 21.35B | 17.01B | 15.18B | 16.84B | 15.13B | 14.78B | 13.8B | 11.46B | 10.67B | 9.8B | 9.15B | 8.38B | 8.58B | 8.85B | 7.07B | 4.4B | 3.57B | 3.46B | 2.99B | 2.9B | 2.81B | 3.68B | 3.81B | 4.1B | 1.86B |
| Total Debt | 12.5B | 12.94B | 12.26B | 12.27B | 11.75B | 13.22B | 7.14B | 6.11B | 6.07B | 4.92B | 4.09B | 4.09B | 3.83B | 2.6B | 2.61B | 1.66B | 1.67B | 1.68B | 1.94B | 1.69B | 1.27B | 815.04M | 828.76M | 861.69M | 699.79M | 731.25M | 599.95M | 1.23B | 1.5B | 1.49B | 225M |
| Net Debt | 5.57B | 8.74B | 10.04B | 7.58B | 6.69B | 9.83B | 2.47B | 2.06B | 3.73B | 878M | 215M | 1.52B | 1.89B | 1.46B | 1.3B | 282M | -4.29M | 64.58M | -33.39M | -352.63M | -471.2M | 83.03M | 248.68M | -69.71M | -21.56M | 79.83M | 415M | 247M | 582M | 859M | -97M |
| Long-Term Debt | 11.55B | 12.37B | 11.14B | 10.21B | 9.03B | 10.54B | 6.06B | 4.97B | 4.38B | 4.77B | 3.49B | 3.79B | 3.83B | 2.6B | 2.61B | 1.66B | 1.67B | 1.68B | 1.94B | 1.69B | 1.27B | 513.79M | 636.7M | 642.64M | 339.91M | 315.49M | 0 | 324M | 1.01B | 1.49B | 225M |
| Short-Term Debt | 949M | 150M | 724M | 1.61B | 2.26B | 2.14B | 729M | 815M | 1.69B | 150M | 600M | 299M | 0 | 0 | 0 | 0 | 447K | 0 | 0 | 0 | 0 | 301.25M | 192.06M | 219.05M | 359.88M | 415.76M | 749M | 901M | 484M | 0 | 0 |
| Total Current Liabilities | 24.05B | 10.31B | 11.26B | 11.95B | 11.63B | 10.49B | 9B | 6.8B | 6.53B | 4.37B | 5.44B | 5.64B | 4.84B | 4.1B | 4.01B | 3.97B | 3.66B | 3.45B | 3.44B | 2.92B | 2.64B | 3.05B | 2.1B | 2.26B | 2.39B | 2.31B | 2.67B | 0 | 0 | 0 | 0 |
| Accounts Payable | 9.39B | 9.81B | 10.27B | 10.07B | 9.08B | 8.1B | 7.95B | 5.74B | 4.55B | 3.84B | 4.56B | 4.98B | 4.47B | 3.89B | 3.78B | 3.75B | 3.47B | 3.22B | 3.21B | 2.7B | 2.49B | 0 | 1.91B | 0 | 0 | 0 | 0 | 0 | 0 | 471M | 1.47B |
| Deferred Revenue | 270M | 356M | 260M | 266M | 286M | 254M | 318M | 247M | 283M | 378M | 280M | 364M | 361M | 206M | 230M | 213M | 185.41M | 228.82M | 238.1M | 219.78M | 155.3M | 0 | 0 | 333.07M | 335.76M | 325.04M | 333M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 13.44B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27M | -197M | -94M | -93M | 0 | -374.46M | -224.54M | -269.23M | 77.85M | 232.4M | 0 | 0 | 552.69M | 0 | 0 | -2.66B | -2.39B | -633M | -1.5B |
| Deferred Taxes | 0 | 0 | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1000K | 0 | 0 | 1000K | 1000K | 1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 2.79B | 7.91B | 7.07B | 7.97B | 6.36B | 5.79B | 4.98B | 4.33B | 3.95B | 7.37B | 5.78B | 4.9B | 4.57B | 4.14B | 4.05B | 3.58B | 3.43B | 3.25B | 3.2B | 4.21B | 3.08B | -624.81M | 828.39M | -642.64M | -245.03M | -315.49M | 148.56M | 214.79M | -573M | -889M | -225M |
| Total Equity | 18.89B | 17.74B | 16.45B | 16.32B | 15.37B | 16.1B | 13.73B | 12.04B | 10.16B | 9.84B | 10.69B | 10.35B | 9.65B | 9.32B | 8.85B | 8.06B | 6.92B | 5.78B | 4.46B | 4.03B | 3.05B | 2.47B | 2.09B | 1.84B | 1.61B | 1.51B | 1.36B | 1.27B | 1.69B | 1.5B | 1.29B |
| Equity Growth % | 19.51% | 7.86% | 0.78% | 6.17% | -4.55% | 17.3% | 14.05% | 18.46% | 3.24% | -7.89% | 3.28% | 7.26% | 3.54% | 5.3% | 9.72% | 16.45% | 19.88% | 29.59% | 10.63% | 31.93% | 23.43% | 18.37% | 13.84% | 14.28% | 6.53% | 10.88% | 7.26% | -24.88% | 12.46% | 16.18% | 0.39% |
| Shareholders Equity | 18.82B | 17.66B | 16.38B | 16.26B | 15.31B | 16.08B | 13.73B | 12.04B | 10.16B | 9.84B | 10.69B | 10.35B | 9.65B | 9.32B | 8.85B | 8.06B | 6.92B | 5.78B | 4.46B | 4.03B | 3.05B | 2.47B | 2.09B | 1.84B | 1.61B | 1.51B | 1.36B | 1.27B | 1.69B | 1.5B | 1.29B |
| Minority Interest | 63M | 80M | 70M | 56M | 59M | 23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | 30.8B | 29.07B | 28.32B | 27.54B | 25.49B | 23.09B | 20.52B | 17.48B | 15.07B | 13.67B | 11.45B | 11.02B | 9.92B | 8.94B | 7.88B | 6.83B | 5.53B | 4.43B | 3.39B | 2.74B | 1.91B | 1.54B | 1.23B | 949.81M | 720.88M | 578.12M | 461M | 371M | 753M | 624M | 451M |
| Common Stock | 33M | 33M | 33M | 33M | 33M | 33M | 33M | 33M | 33M | 33M | 33M | 33M | 33M | 33M | 32M | 32M | 31.71M | 31.63M | 31.31M | 31.12M | 30.49M | 29.84M | 29.34M | 28.98M | 28.56M | 28.45M | 28M | 28M | 28M | 27M | 27M |
| Accumulated OCI | -1.27B | -633M | -1.07B | -999M | -1.3B | 42M | 391M | 156M | -159M | 19M | -66M | 58M | 223M | 158M | 386M | 303M | 120.58M | 42.13M | -175.24M | 14.02M | -13.21M | 24.83M | 16.53M | 16.91M | 22.45M | 11.67M | -8M | -28M | 13M | 9M | -8M |
| Return on Equity (ROE) | 6.68% | 6.95% | 7.37% | 15.71% | 17.83% | 19.66% | 26.14% | 24.39% | 16.83% | 23.85% | 5.84% | 12.77% | 12.1% | 13.55% | 14.45% | 18.94% | 17.31% | 20.32% | 15.25% | 23.54% | 17.63% | 13.52% | 14.26% | 13% | 9.17% | 8.17% | 6.85% | -25.87% | 8.09% | 12.39% | 0.93% |
| Return on Assets (ROA) | 2.28% | 2.5% | 2.59% | 5.49% | 6.34% | 7.35% | 10.5% | 9.95% | 6.47% | 9.33% | 2.41% | 5.25% | 5.19% | 6.11% | 6.54% | 8.36% | 7.27% | 7.65% | 4.99% | 7.25% | 5.74% | 4.92% | 5.11% | 4.52% | 3.17% | 2.73% | 1.99% | -7.36% | 2.36% | 4.04% | 0.4% |
| Equity / Assets | 32.97% | 36.38% | 35.51% | 34.8% | 35.15% | 35.99% | 39.14% | 41.45% | 40.09% | 36.88% | 41.4% | 41.18% | 41.13% | 44.85% | 45.33% | 45.15% | 43.08% | 40.81% | 34.18% | 31.28% | 30.15% | 36.02% | 36.94% | 34.68% | 34.92% | 34.24% | 32.64% | 25.88% | 30.71% | 27.7% | 40.98% |
| Debt / Equity | 0.66x | 0.73x | 0.75x | 0.75x | 0.76x | 0.82x | 0.52x | 0.51x | 0.60x | 0.50x | 0.38x | 0.40x | 0.40x | 0.28x | 0.30x | 0.21x | 0.24x | 0.29x | 0.43x | 0.42x | 0.42x | 0.33x | 0.40x | 0.47x | 0.44x | 0.48x | 0.44x | 0.97x | 0.89x | 0.99x | 0.17x |
| Book Value per Share | 155.04 | 146.80 | 136.06 | 131.13 | 120.93 | 124.45 | 103.21 | 89.34 | 73.42 | 67.60 | 70.80 | 68.45 | 61.88 | 58.54 | 54.12 | 48.04 | 40.78 | 34.16 | 26.38 | 23.72 | 18.17 | 15.00 | 12.84 | 11.32 | 9.34 | 9.01 | 8.16 | 7.56 | 10.08 | 9.05 | 7.82 |
| Tangible BV per Share | 68.47 | 57.30 | 44.44 | 40.78 | 35.12 | 18.33 | 67.30 | 58.87 | 43.49 | 43.51 | 47.26 | 44.49 | 38.33 | 30.73 | 27.38 | 29.13 | 23.30 | 20.94 | 12.98 | 12.53 | 9.80 | 6.70 | 7.21 | 6.53 | 4.82 | 4.37 | 3.42 | 2.75 | 2.99 | 1.67 | 4.86 |
Quick answers to the most common questions about buying HUM stock.
As of 2025, Humana Inc. (HUM) had total assets of $48.75B including $7.47B in current assets.
Humana Inc. (HUM) carries total debt of $12.94B, offset by $4.20B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Humana Inc. (HUM) has total shareholders' equity (book value) of $17.66B ($146.80 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Humana Inc. (HUM) reported a current ratio of 0.72x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Thin margins amid reserve volatility
Metrics are mathematically derived from official filings.
Asset Base Growing Faster Than Equity
Based on Humana's reported figures, total assets rose from $50.0B in 2024Q3 to $57.3B in 2026Q3, while equity grew more modestly from $17.6B to $18.8B, suggesting the balance sheet is expanding through liabilities rather than retained capital generation.
The gap between asset growth and equity growth implies that much of the expansion reflects higher policyholder obligations and float rather than internally generated capital. Equity returns have been uneven, with ROE swinging from 7.3% in 2025Q1 to negative 4.4% in 2025Q4, which limits the capacity of earnings to reinforce the capital base. Investors should monitor whether the asset expansion continues to outpace equity, as that would tighten the cushion available against adverse claims development.
Loss Ratio Swings Test Reserve Adequacy
According to reported quarterly data, Humana's loss ratio moved between 82.6% in 2025Q1 and 88.3% in both 2025Q4 and 2026Q3, indicating that claims cost relative to premiums has been volatile across the period.
A loss ratio that repeatedly climbs toward 88% leaves a narrow margin for reserve estimation error, and the quarterly pattern is consistent with year-end cost pressure. Without isolated prior-period development data in the supplied figures, it is not possible to determine whether these swings reflect true utilization trends or reserve true-ups. Investors should monitor reserve development disclosures closely, as persistent upward loss ratio drift would warrant further investigation into IBNR adequacy.
Low Leverage Offset by Modest Returns
Based on Humana's reported figures, the debt-to-equity ratio of 0.73 and ROE of 7.0% indicate moderate leverage paired with returns that appear thin relative to the capital base held.
Leverage at this level suggests the balance sheet retains some capacity for absorbing shocks, but the sub-8% ROE indicates that the equity base is not generating strong returns in the current cycle. Statutory capital adequacy metrics such as RBC ratios are not included in the supplied data, so capacity for buybacks or acquisitions cannot be assessed with confidence. The conservative leverage profile may provide flexibility, though its benefit depends on earnings stabilizing.
Cash Position Undisclosed Against Claims Outflows
As reported in financial statements, claims and loss outflows reached $36.3B in 2026Q3, yet the supplied cash line shows no reported balance, leaving the liquid asset coverage of expected payouts data unavailable.
Because cash and reinsurance recoverable figures are not provided, the ratio of liquid assets to near-term claims cannot be measured from the supplied data. Claims outflows rising roughly 45% over the period increase the importance of this coverage measure, but drawing conclusions about liquidity sufficiency would be speculative. Investors should review the detailed investment and reinsurance schedules to evaluate claims-paying liquidity directly.
Reserve Estimation Risk Could Reverse Earnings
Based on Humana's reported figures, net losses of $693M in 2024Q4 and $796M in 2025Q4 coincided with combined ratios above 100%, suggesting year-end reserve or cost pressure that may recur.
The recurrence of fourth-quarter losses alongside combined ratios exceeding 103% raises the possibility that reserve adequacy, rather than one-off events, is driving balance sheet strain at year end. Because the supplied data does not isolate prior-period development or risk-adjustment clawbacks, the magnitude of potential reserve deficiencies cannot be quantified. This warrants further investigation, as an adverse reserve revision could erode equity more quickly than the current leverage profile would indicate.